Paratek Pharmaceuticals, Inc. (PRTK)
| Previous Close | 2.3500 |
| Open | 2.3000 |
| Bid | 2.2800 x 1000 |
| Ask | 2.4700 x 900 |
| Day's Range | 2.2700 - 2.3600 |
| 52 Week Range | 1.6000 - 5.4100 |
| Volume | |
| Avg. Volume | 375,666 |
| Market Cap | 125.635M |
| Beta (5Y Monthly) | 1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1780 |
| Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Oct 31, 2014 |
| 1y Target Est | 18.50 |
- Simply Wall St.
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Is Expected To Breakeven In The Near Future
Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) is possibly approaching a major achievement in its business, so we would...
- GlobeNewswire
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on August 31, 2022, the Company granted stock options to one new employee of the Company. The award was granted pursuant to the Paratek Pharmaceuticals, Inc. 20
- GlobeNewswire
Paratek Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Paratek President and Chief Commercial Officer Adam Woodrow will participate in a virtual fireside chat at the H.C. Wainwright 24th Annual Global Investment Conf
